sts-135 (also called n-(adamantan-1-yl)-1-(5-fluoropentyl)-1h-indole-3-carboxamide or 5f-apica) is a drug that acts as a potent agonist for the cannabinoid receptors which produces subjective effects somewhat similar to that of cannabis with a short duration and an emphasis on intense physical sensations. there is very little information regarding the pharmacology of this compound within the scientific literature. despite this, however, it is available for sale as a grey area research chemical through online vendors.
cannabinoids are commonly smoked or vaporized to achieve a quick onset of effects and rapid offset. sts-135 is orally active when dissolved in a lipid, which can increase the duration significantly. like other cannabinoids, it is insoluble in water but dissolves in ethanol and lipids.
unlike cannabis, the chronic abuse of synthetic cannabinoids has been associated with multiple deaths and more dangerous side effects and toxicity in general. therefore, it is strongly discouraged to take this substance for extended periods of time or in excessive doses.
sts-135, or n-(adamantan-1-yl)-1-(5-fluoropentyl)-1h-indole-3-carboxamide, is a synthetic cannabinoid drug containing a substituted indole group. this indole moeity is substituted at r1 with a fluoropentyl chain, a substitution shared with 5f-pb-22, thj-2201, and 5f-akb48. additionally, the indole is substituted at r3 with a carboxamide group. this carboxamide group is n-substituted at its terminal amine group with an adamantane group. this group consists of four fused cyclohexane rings in a unique structure called a diamondoid. sts-135 is an analog of 5f-akb48 in which the core indazole structure is substituted with an indole base.
although this substance has not been formally studied, from analysis of the structure, it is presumed that sts-135 has a similar binding profile to that of other cannabinoids and matches many of the in vivo properties of δ9-thc.
formal studies have demonstrated that sts-135 acts a potent cannabinoid receptor agonist in vitro with an ec50 of 51 nm for human cb2 receptors and 13 nm for human cb1 receptors. sts-135 produces bradycardia and hypothermia in rats at doses of 1-10 mg/kg, suggesting cannabinoid-like activity. however, the role of these interactions and how they result in the cannabinoid high experience continues to remain elusive.